Rallybio
Unimagined Therapies. Undreamed Outcomes.
New Haven, United States · Founded 2018 · $182.0M raised
- Headquarters
- New Haven, Connecticut
- Employees
- 51–200
- Founded
- 2018
- Business Model
- B2B
- Website
- rallybio.com
- Total Funding
- $182.0M
- Last Round
- $145.0M Series BMay 2020
- Rounds
- 2
About
Rallybio is a clinical-stage biotechnology company advancing therapies for patients with severe and rare diseases, focused on complement dysregulation and hematology. The company combines deep drug development expertise with a global network of academic partners to translate scientific breakthroughs into life-changing treatments.
Summary
Rallybio is a Biotech company based in New Haven, United States, founded in 2018. It has raised $182.0M in total across 2 rounds, most recently a $145.0M Series B round in May 2020. Investors include Pivotal bioVenture Partners, F-Prime Capital and Viking Global.
Tech & App Stack
1 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
May 2020
Sign up to see all 2 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
One of the world's largest contract research organizations (CROs), providing end-to-end clinical ...
Global contract development and manufacturing organization (CDMO) focused exclusively on sterile ...
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Specialty pharmaceutical company